ArticleJournal of hepatocellular carcinoma2026
Multidisciplinary Treatment for Liver Cancer in China: A Cross-Sectional Survey of Practices, Gaps and Future Directions.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the current status of the establishment and operation of multidisciplinary treatment (MDT) for liver cancer in China, identify key bottlenecks, and provide a scientific basis for promoting the transition of MDT from "demonstration and exploration" to "standardized construction". Methods: This study adopted a cross-sectional survey design to systematically investigate the current establishment and operational status of MDT for liver cancer in China. A total of 1,073 hospitals across 31 provincial-level administrative regions in China were selected as study sites. The study participants included 1,279 clinicians and relevant medical staff directly engaged in the clinical practice of liver cancer MDT. Results: A total of 1,279 questionnaires were distributed, with 1,073 valid responses collected (validity rate: 83.89%). The results revealed the following characteristics of liver cancer MDT in China: (1) Organizational Structure: 51.35% of hospitals had implemented liver cancer MDT, with 24.14% establishing fixed teams. The predominant model was department-led (65.25%); (2) Clinical Practice: Annual case discussions showed a polarized distribution (≤50 cases: 41.70%; >200 cases: 16.99%). A majority (90.73%) recognized MDT's significant impact on clinical decision-making, while 83.01% of respondents, based on their subjective experience, held the perception that MDT might be associated with survival improvement in patients; (3) Quality Control Systems: 79.92% of hospitals had basic quality control mechanisms, but only 2.96% had independent quality control departments. Information technology infrastructure required improvement (only 35.91% achieved data platform integration); (4) Key Bottlenecks: Insufficient policy support (41.18%), staffing challenges (19.92%), and scheduling difficulties (13.82%). Conclusion: While liver cancer MDT has been preliminarily established in hospitals in China, challenges such as regional disparities, hospital-level gradient, weak quality control, and inadequate IT infrastructure persist. A tripartite strategy-incorporating tiered healthcare delivery, standardized protocols, and technological innovation-is recommended to achieve a qualitative transformation and support the "Healthy China 2030" initiative in liver cancer prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.